BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Robert C, Hwu WJ, Hamid O, Ribas A, Weber JS, Daud AI, Hodi FS, Wolchok JD, Mitchell TC, Hersey P, Dronca R, Joseph RW, Boutros C, Min L, Long GV, Schachter J, Puzanov I, Dummer R, Lin J, Ibrahim N, Diede SJ, Carlino MS, Joshua AM. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. Eur J Cancer 2021;144:182-91. [PMID: 33360855 DOI: 10.1016/j.ejca.2020.11.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zaremba A, Eggermont AMM, Robert C, Dummer R, Ugurel S, Livingstone E, Ascierto PA, Long GV, Schadendorf D, Zimmer L. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. Eur J Cancer 2021;155:268-80. [PMID: 34392069 DOI: 10.1016/j.ejca.2021.07.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Ernst M, Giubellino A. The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma. Biomedicines 2022;10:822. [DOI: 10.3390/biomedicines10040822] [Reference Citation Analysis]
3 Ksienski D, Truong PT, Croteau NS, Chan A, Sonke E, Patterson T, Clarkson M, Hackett S, Lesperance M. Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab. J Geriatr Oncol 2021:S1879-4068(21)00222-8. [PMID: 34654653 DOI: 10.1016/j.jgo.2021.10.002] [Reference Citation Analysis]
4 Dearden H, Au L, Wang DY, Zimmer L, Eroglu Z, Smith JL, Cuvietto M, Khoo C, Atkinson V, Lo S, Long GV, Sandhu S, Ascierto PA, Carlino MS, Johnson DB, Larkin J, Menzies AM. Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. Eur J Cancer 2021;153:168-78. [PMID: 34182268 DOI: 10.1016/j.ejca.2021.04.045] [Reference Citation Analysis]
5 Dimitriou F, Staeger R, Ak M, Maissen M, Kudura K, Barysch MJ, Levesque MP, Cheng PF, Dummer R, Mangana J. Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. Cancers (Basel) 2021;13:2931. [PMID: 34208218 DOI: 10.3390/cancers13122931] [Reference Citation Analysis]
6 Yang F, Wang JF, Wang Y, Liu B, Molina JR. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers (Basel) 2021;14:109. [PMID: 35008273 DOI: 10.3390/cancers14010109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Jansen Y, van der Veldt AAM, Awada G, Neyns B. Anti-PD-1: When to Stop Treatment. Curr Oncol Rep. [DOI: 10.1007/s11912-022-01264-6] [Reference Citation Analysis]
8 Dietz H, Weinmann SC, Salama AK. Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease. Cancer Manag Res 2021;13:8199-208. [PMID: 34754240 DOI: 10.2147/CMAR.S283217] [Reference Citation Analysis]
9 Hu H, Ling B, Shi Y, Wu H, Zhu B, Meng Y, Zhang GM. Plasma Exosome-Derived SENP1 May Be a Potential Prognostic Predictor for Melanoma. Front Oncol 2021;11:685009. [PMID: 34422639 DOI: 10.3389/fonc.2021.685009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS, Tsang VHM, Menzies AM. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab 2021:dgab263. [PMID: 33878162 DOI: 10.1210/clinem/dgab263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Zhao Q, Wang Q, Wang T, Xu J, Li T, Liu Q, Yao Q, Wang P. Pattern Recognition Receptors (PRRs) in Macrophages Possess Prognosis and Immunotherapy Potential for Melanoma. Front Immunol 2021;12:765615. [PMID: 34858419 DOI: 10.3389/fimmu.2021.765615] [Reference Citation Analysis]
12 Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK. Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up. Int J Cancer 2021. [PMID: 34449877 DOI: 10.1002/ijc.33768] [Reference Citation Analysis]
13 Kim BW. Overt Hyperthyroidism May Be a Good Prognostic Sign in Immune Checkpoint Inhibitor Treatment. Clinical Thyroidology 2021;33:467-9. [DOI: 10.1089/ct.2021;33.467-469] [Reference Citation Analysis]
14 Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov 2021. [PMID: 34316029 DOI: 10.1038/s41573-021-00259-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Mesti T, Ceplak Mencin V, Mileva Boshkoska B, Ocvirk J. Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes. Radiol Oncol 2021;55:354-61. [PMID: 33939899 DOI: 10.2478/raon-2021-0019] [Reference Citation Analysis]
16 Bastacky ML, Wang H, Fortman D, Rahman Z, Mascara GP, Brenner T, Najjar YG, Luke JJ, Kirkwood JM, Zarour HM, Davar D. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis. Front Oncol 2021;11:749064. [PMID: 34900695 DOI: 10.3389/fonc.2021.749064] [Reference Citation Analysis]
17 McCulloch JA, Davar D, Rodrigues RR, Badger JH, Fang JR, Cole AM, Balaji AK, Vetizou M, Prescott SM, Fernandes MR, Costa RGF, Yuan W, Salcedo R, Bahadiroglu E, Roy S, DeBlasio RN, Morrison RM, Chauvin JM, Ding Q, Zidi B, Lowin A, Chakka S, Gao W, Pagliano O, Ernst SJ, Rose A, Newman NK, Morgun A, Zarour HM, Trinchieri G, Dzutsev AK. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat Med 2022. [PMID: 35228752 DOI: 10.1038/s41591-022-01698-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
18 Haist M, Stege H, Maikranz V, Halley Blanco M, Grabbe S, Loquai C. Poliosis Is Associated with Response to Checkpoint-Inhibitor Therapy: A Case Report of Two Patients with Multifocal Metastatic Melanoma. Immuno 2022;2:307-16. [DOI: 10.3390/immuno2020020] [Reference Citation Analysis]
19 Mcneel DG, Eickhoff JC, Wargowski E, Johnson LE, Kyriakopoulos CE, Emamekhoo H, Lang JM, Brennan MJ, Liu G. Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC). J Immunother Cancer 2022;10:e004198. [DOI: 10.1136/jitc-2021-004198] [Reference Citation Analysis]